Background Febrile seizures are common in young children. Annual peaks in incidence
mirror increased respiratory virus activity during winter. Limited virological data are available …

Introduction Despite children aged 6–35 months developing more severe influenza
infections, not all countries include influenza vaccines in their national immunization …

Introduction Influenza vaccination has been shown to be safe and effective against influenza
and in the prevention of complicating secondary respiratory illnesses. However, its uptake in …

Vaccination is a highly effective public health strategy that provides protection to both
individuals and communities from a range of infectious diseases. Governments monitor …

Objective To actively solicit adverse events experienced in the days following immunisation
with quadrivalent inactivated influenza vaccine using Australia's near real-time, participant …

Increased febrile reactions in Australian children from one influenza vaccine brand in 2010
diminished confidence in influenza immunisation, highlighting the need for improved …

Background: Data demonstrating the effectiveness of inactivated trivalent influenza vaccine
(TIV) for children at increased risk of severe disease are limited. Our objective was to …

Influenza vaccine safety is an ongoing issue. In 2010, inactivated trivalent influenza
vaccines (TIV s), Fluvax® and Fluvax Junior® manufactured by CSL Biotherapies ('CSL') …

Aim Influenza causes a substantial burden in young children. Vaccine efficacy (VE) data are
limited in this age group. We examined trivalent influenza vaccine (TIV) efficacy and safety in …

Annual seasonal influenza epidemics cause substantial disease and economic burden
worldwide. During the coronavirus disease 2019 (COVID-19) pandemic in 2020 and 2021 …